Sanyoubio

Sanyou Bio Congratulates KangaBio on their IND Approval for Next-Generation IL-12 Prodrug Cancer Immunotherapy

by

SHANGHAI, Nov. 4, 2023 /PRNewswire/ — On October 26, 2023, KangaBio announced that the U.S. FDA has granted official approval for their independent R&D clinical trial application (IND) for KGX101. KGX101 is a recombinant IL-12 Fc fusion protein designed for intravenous injection. The KGX101 clinical trials will be carried out simultaneously in both United States … Read more

Sanyou Milestones | Super Trillion Common Light Chain Antibody Discovery Platform Launched

by

SHANGHAI, June 11, 2023 /PRNewswire/ — On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of “Sanyou Super Trillion Common Light Chain Antibody Discovery Platform” (the “platform”). As one of the nine trillion antibody discovery platforms of Sanyou, the platform features a library capacity of up to 1.12E+12 CFU. For … Read more